



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON May 3, 2005

[Signature]

May 3, 2005
DATE

Attorney Docket No.: P32181C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lewis et al. May 3, 2005
Appln. No.: 10/691,159 Group Art Unit: 1615
Filed: October 22, 2003 Examiner: J.M. Spear
For: PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER AND ANOTHER ANTIDIABETIC AGENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)

Sir:

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. In accordance with 37 C.F.R. §1.98(a)(2), copies of the cited U.S. patents and published patent applications are not enclosed. A copy of each cited foreign and non-patent document is enclosed.

This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.


05/06/2005 AWONDAF1 00000010 192570 10691159

01 FC:1806 180.00 DA

U.S. Appl'n. No.: 10/691,159
Filing Date: 22 October 2003

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\KLS\Cases\IP32181C1\Supp IDS.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32181C1	SERIAL NO. 10/691,159
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Lewis <i>et al.</i>	
		FILING DATE October 22, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,287,599	9/11/01	Burnside et al.	424	468	
	5,695,781	12/9/97	Zhang et al.	424	468	
	5,543,155	8/6/96	Fekete et al.	424	473	
	5,004,614	4/2/91	John N. Staniforth	424	466	
	US20020177612	11/28/02	Granett et al.	514	340	


FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 98/42340	10/1/98	PCT				
	WO 97/10819	3/27/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	“Excipients – Polyvinyl Acetate Phthalate (PVAP)-Based Coatings”. <i>Pformulate</i> , October 27, 2000.
	Goskonda et al., “Pharmaceutical Excipients – Hypromellose Phthalate”. http://www.medicinescomplete.com/mc/excipients/current/noframes/EXC0112.htm . October 25, 2002.
	R.J. Harwood. “Hydroxypropyl Methylcellulose”. <i>Handbook of Pharmaceutical Excipients</i> , Third Edition. Pages 252-255 (2000). Ed. A.H. Kibbe, American Pharmaceutical Association, Washington, DC.
	Goskonda et al. “Cellulose Acetate Phthalate”. <i>Handbook of Pharmaceutical Excipients</i> , Third Edition. Pages 99-101 (2000). Ed. A.H. Kibbe, American Pharmaceutical Association, Washington, DC.
	Chang et al. “Polymethacrylates”. <i>Handbook of Pharmaceutical Excipients</i> , Third Edition. Pages 401-406 (2000). Ed. A.H. Kibbe, American Pharmaceutical Association, Washington, DC.
	USP Dictionary of USAN and International Drug Names. Page 133 (1998). U.S. Pharmacopeia, Rockville, MD.
	USP Dictionary of USAN and International Drug Names. Page 132 (1998). U.S. Pharmacopeia, Rockville, MD.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. P32181C1	SERIAL NO. 10/691,159
	APPLICANT Lewis <i>et al.</i>	
	FILING DATE October 22, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	20040102486	5/27/04	Benincosa et al.	514	342	
	20040091531	5/13/04	Glinecke et al.	424	468	
	5,955,106	9/21/99	Moeckel et al.	424	464	
	5,965,584	10/12/99	Ikeda et al.	514	342	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 01/35941	5/25/01	PCT				
	WO 01/35940	5/25/01	PCT				
	WO 03/068195	8/21/03	PCT				
	EP 0749751	12/27/96	EP				
	EP 0306228	11/17/99	EP				
	EP 0753298	11/21/01	EP				
	WO 98/36755	8/27/98	PCT				
	WO 94/05659	3/17/94	PCT				
	WO 98/56378	12/17/98	PCT				
	WO 98/57649	12/23/98	PCT				
	WO 00/28989	5/25/00	PCT				
	WO 95/21608	8/17/95	PCT				
	TW 054086	1/21/92	Taiwan			X	
	TW 088794	7/11/97	Taiwan			Abs.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	J.R. White. "The Pharmacological Reduction of Blood Glucose in Patients with Type 2 Diabetes Mellitus". <i>Clinical Diabetes</i> , 16(2): 58-67 (1998).
	"Treatment Options for Type-2 Diabetes – Pharmacologic Treatment Options". <i>American Family Physician</i> , Monograph No.1, 2000.
	"Excipients – Methacrylate-Based Coatings". <i>Pformulate</i> , August 3, 2002.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32181C1	SERIAL NO. 10/691,159
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Lewis <i>et al.</i>	
		FILING DATE October 22, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US2003109553	6/12/03	Stephen Alistair Smith	514	342	
	6,677,358	1/13/04	Peter Giortz Muller	514	331	
	US2001048946	12/6/01	Isaac Ghebre-Sellassie	424	486	
	6,011,049	1/4/00	Randall Wayne Whitcomb	514	369	
	5,972,973	10/26/99	Randall Wayne Whitcomb	514	342	
	5,859,037	1/12/99	Randall Wayne Whitcomb	514	369	
	5,326,770	7/5/94	Wendall W. Wilkerson	514	314	
	6,475,521	11/5/02	Timmins et al.	424	469	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	0 816 340	1/7/98	EP				
	WO 03/068195	8/21/03	PCT				
	WO 03/045945	6/5/03	PCT				
	WO 05/013935	2/17/05	PCT				
	WO 05/013956	2/17/05	PCT				
	WO 03/007919	1/30/03	PCT				
	WO 04/045608	6/3/04	PCT				
	WO 04/026241	4/1/04	PCT				
	WO 04/006921	1/22/04	PCT				
	WO 04/012700	2/12/04	PCT				
	WO 03/105809	12/24/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	“Fortamet”. PDR Electronic Library, http://www.thomsonhc.com/pdrel/librarian/ND/R/PdrPFPUI/B11zUVaAgMDyG/DDA... February, 2004.
	Glucophage product label drug description. March, 2004.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32181C1	SERIAL NO. 10/691,159
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Lewis <i>et al.</i>	
		FILING DATE October 22, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,451,342	9/17/02	Adjei et al.	424	474	
	US20040219212	11/4/04	Castan et al.	424	471	
	6,461,639	10/8/02	Adjei et al.	424	472	
	US2001/0036478	11/1/01	Adjei et al.	424	481	
	6,524,621	2/25/03	Adjei et al.	424	490	
	6,780,432	8/24/04	Cutie et al.	424	468	
	US2001/0046515	11/29/01	Adjei et al.	424	465	
	6,296,874	10/2/01	Cutie et al.	424	474	
	US2001/0034374	10/25/01	Adjei et al.	514	635	
	6,403,121	6/11/02	Adjei et al.	424	468	
	US2003/0215563	11/20/03	Frank J. Bunick	427	2.1	
	US2003/0215585	11/20/03	Frank J. Bunick	428	34.1	
	6,277,409	8/21/01	Luber et al.	424	476	
	6,471,991	10/29/02	Robinson et al.	424	464	
	6,742,646	6/1/04	Sowden et al.	198	377.04	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 03/005994	1/23/03	PCT				
	WO 03/005991	1/23/03	PCT				
	WO 01/82867	11/8/01	PCT				
	WO 01/35940	5/25/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	"Specifications and Test Methods for EUDRAGIT® RL 30 D and EUDRAGIT® RS 30 D". Pages 1-4 (September 2004).
	"Specifications and Test Methods for EUDRAGIT® RL 30 D and EUDRAGIT® RS 30 D. pp 1-3 (January 1996).
	"Specifications and Test Methods for EUDRAGIT® L 30 D 55. Pages 1-3 (January 1996).
	"Specifications and Test Methods for EUDRAGIT® L 100 and EUDRAGIT® S 100". Pages 1-4 (September 2004).
	Datasheet for Registration of EUDRAGIT® Acrylic Polymers. International Availability and Acceptance for Use in the Manufacture of Pharmaceutical Dosage Forms. (1999)
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	